Background: Colorectal cancer remains a leading cause of mortality and morbidity.
| INTRODUCTION
Colorectal cancer is a leading cause of mortality and morbidity worldwide, with an estimated European incidence of 43.5 per 100 000 in 2012 and mortality of 19.5 per 100 000. 1 The lifetime risk, for UK residents, is 1 in 15 for men or 1 in 19 for women. 2 Across Europe, colorectal cancer is the second most common cause of cancer-related mortality. 1 Colorectal cancer carries a significant financial burden for the National Health Service, with a mean annual cost of £12 000 and £8800 for each patient diagnosed with rectal and nonrectal colon cancer respectively. 3 Data from the UK Bowel
Cancer Screening Programme have clearly demonstrated that detection of colorectal cancer at an earlier stage and identification of advanced pre-malignant adenomas can reduce future cancer-associated mortality and morbidity. 4, 5 The UK Bowel Cancer Screening Programme uses a faeces-based screening tool to select patients to take forward to colonoscopy, in line with European guidance. 6 Currently, in England, the guaiacbased faecal occult blood testing (gFOBt) is employed. This test relies on bleeding from neoplastic lesions and can be used to identify people with >10 mL rectal blood loss daily. gFOBt is however, prone to false positive results after ingestion of certain foods. 7 The low sensitivity of gFOBt has led to criticism of its use for populationbased screening. 8 The gFOBt is likely to be replaced by faecal immunochemical testing (FIT). FIT detects twice as many advanced cancers as guaiac testing 9 and can provide both qualitative and quantitative results. A recent observational study, from Italy, demonstrated a reduction in colorectal cancer-related mortality in regions where screening with FIT was adopted compared with regions where screening had not yet been implemented. 10, 11 Burch et al 4 reported a meta-analysis of 59 studies of FOBT: sensitivities for the detection of all neoplasms ranged from 6.2% to 83.3% for gFOBTs and 5.4% to 62.6% for FITs, depending on the preferred specificity. 12 A review by NICE concluded that FIT has a specificity ranging from 43% to 86%. 13 However, FIT has limitations: the Dutch colorectal cancer screening programme reported 77% sensitivity with FIT based on 18 716 samples (specificity was not reported) and 23%
of the patients developed interval cancers. 14 Several studies have reported volatile organic compounds emitted from different substrates as biomarkers for colorectal cancer.
One such study used selected ion flow tube mass spectrometry (SIFT-MS) to detect volatile organic compounds in faeces. 15 Another analysed urine, from patients with colorectal cancer, employing Field Asymmetric Ion Mobility Spectrometer (FAIMS). 16 The third used breath analysed by thermal-desorber gas chromatography-mass spectrometry (GCMS) in an attempt to diagnose colorectal cancer. 17, 18 These were mainly proof of concept or feasibility studies that reported output patterns rather than identifying the individual compounds. Therefore, understanding the biological plausibility for patterns of volatile organic compounds can be difficult to interpret.
We undertook a prospective study of the volatile organic compounds emitted from faecal samples obtained from patients at risk of colorectal cancer. 
| MATERIALS AND METHODS

| Participants
| Sample collection and storage
Samples were produced, at home, during the 48 hours preceding their colonoscopy and before commencing the required bowel preparation. The stool was produced initially into a foil dish, then participants were asked to place at least three spoonfuls of faeces into a glass vial (OdoReader, University of the West of England), before it was sealed and stored in a cool place, either outside or in the fridge.
The initial volume of stool supplied by the patient was not specified but could not exceed the volume of the provided 20 mL glass vial. 
| Headspace volatile organic compound analysis
Four hundred and fifty milligram of unadulterated faeces was aliquoted into new 10 mL headspace vials and sealed with magnetic caps (Supleco, Poole, UK). 19 Both the sample intended for analysis and the residual faeces were then stored at −20°C until GCMS analysis was performed.
Headspace volatile organic compounds analysis was performed using a Combipal (CTC, Zwingen, Switzerland) and carboxen/polydimethylsiloxane solid phase microextraction fibre (Sigma Aldrich, Dorset, UK). The fibre was exposed to the headspace above the fae- 
| Data processing
The GCMS data were processed using a pipeline involving the Auto- Metab, in order to align metabolites and recalculate their relative abundances based on the intensity of a specific ion mass fragment per metabolite. In order to develop robust parsimonious statistical models, those compounds found to be present in fewer than 20% of the patients in both groups were removed. 20, 21 Compounds were named using IUPAC nomenclature. Metaboanalyst was used the data were normalised by median and log-transformed. When Mann-Whitney and factor analysis was used the data were logged, normalised and the absence of a volatile organic compound substituted by the value -3 to create an artificial floor in keeping with the concept that the lack of an observable volatile organic compound is analogous to the least amount measurable.
| Statistical analysis
| RESULTS
One hundred and thirty-seven patients were included in the study:
the average age was 64.3 years; 56% were male. The mean age was lowest in those with no neoplasia and greatest in those with the cancer, P = 0.02. None of the participants reported being smokers or vegetarians. Self-reported ethnicity was noted: all but one was White British. 27.7% of study participants were recruited from the Bowel Cancer Screening Programme.
One hundred and sixty-two volatile organic compounds were Initially samples from patients in all three groups were compared using ANOVA. Fourteen volatile organic compounds differed in abundance: after adjusting for multiple comparisons, none were significant, but several were of interest as they were found in later comparisons, including 5-methyl-2-propan-2-yl-cyclohexan-1-ol, ethyl 3-methylbutanoate and propan-2-ol (Table 1) .
| Volatile organic compounds as a biomarker for colonic adenocarcinoma: quantitative analysis
PLS-DA comparing those with no neoplasia and those with colorectal cancer showed a separation that suggested potential diagnostic utility ( Figure 1 ). Exploration of potential candidates for biomarker analysis can be seen in Table 2 . These comparisons did not include samples from patients with adenomatous polyps: only those with confirmed adenocarcinoma and no neoplasia were included for analysis.
Propan-2-ol and 5-methyl-2-propan-2-yl-cyclohexan-1-ol was further considered in isolation, following assessment when combining volatile organic compound as a ratio. The latter was formerly known BOND ET AL.
| 1007
as dl-menthol: we will use that name to aid readability. Propan-2-ol selected as it was the volatile organic compound most strongly associated with cancer; dl-menthol as it was the only volatile organic compound to be negatively associated with cancer.
The abundance of propan-2-ol was compared in the three groups ; the differences were significant, P = 0.001 ( Figure 2 ). The data were logtransformed and compared using ANOVA: the differences were significant (P = 0.01), post hoc Dunnett testing showed the main difference was between samples from patients with cancer and controls (P = 0.007): this implies that, while the mean for adenomas was appeared less than that for controls, the adenoma data were widely spread. It is noteworthy, of the other compounds associated with cancer, three are esters of propan-2-ol with short chain acids.
The abundance of dl-menthol was subjected to the same analysis. The mean abundance in cancer was 0. ; the differences were significant, P = 0.04. The data were log-transformed and compared using ANOVA: the differences were significant (P = 0.003), post hoc Dunnett testing showed patients with cancer had significantly less dlmenthol than adenoma and control groups.
Propan-2-ol showed the most promise as a single biomarker for colorectal cancer: it achieved an area under the ROC (AUROC) curve Change in bowel habit-diarrhoea F I G U R E 2 Box plots to show the relative abundance of propan-2-ol in faeces from all participants. All patients in each cohort are included Normal (no neoplasia) n = 60, adenoma n = 56 and cancer n = 21
( Figure 3 ) to predict colorectal cancer of 0.76 with a sensitivity of 83% and specificity of 71%.
Calculating ratios of all possible metabolite pairs and then choosing top ranked ratios, based on p values, allowed for further biomarker assessment.
A hold-out technique was applied to the 81 samples (21 cancer and 60 controls) in order to validate the combination of 3-methyl butanoic acid/propan-2-ol as a biomarker for colorectal cancer: 50% of each cohort were held back. The combination of 3-methylbutanoic acid and propan-2-ol gave the best result: data from patients with cancer and with no neoplasia were modelled using logistic regression and 10-fold cross-validation, based upon the abundance of 3-methylbutanoic acid and propan-2-ol ( 
| Assessing for patterns of volatile organic compounds as biomarkers for colonic adenocarcinoma-factor analysis using qualitative data
Principal component analysis and a non-orthogonal rotation feature analysis was applied to qualitative (presence/absence) data for volatile organic compounds using all volatile organic compounds that was present in at least 30% of the group for any of the three diagnostic groups. Using all the data, the solution could not be extracted It is noteworthy that these three volatile organic compounds were also found by the univariate analysis, before correction for multiple comparisons.
Pure reference solutions of propan-2-ol, hexan-2-one and ethyl 3-methylbutanoate confirmed the identification within the stool samples was correct.
| Volatile organic compounds as a biomarker for colonic adenomas: quantitative analysis
Several volatile organic compounds were associated with samples from patients with >4 polyps (Figure 4) . None of the associations remained after adjustment for multiple comparisons. adenomatous colonic polyps. 5 This study has demonstrated the utility of volatile organic compounds emitted from faeces to act as a biomarker for colonic neoplasia, in particular adenocarcinoma.
| DISCUSSION
We have reported two volatile organic compound-based models for the identification of samples from patients with adenomas and colorectal cancer. In the quantitative approach, the models were dominated by the presence of propan-2-ol either as an alcohol or as an ester with short chain fatty acids. The qualitative model, which simply used presence or absence of compounds, also included propan-2-ol.
Propan-2-ol is a secondary alcohol that may be derived from acetone: a pathway associated with Clostridria. 24 The role of propan-2-ol in the pathogenesis of colorectal cancer had not been proposed before: the occurrence in this study may be a bystander phenomenon linked to dysbiosis; further work is needed. in samples from high risk compared to low risk subjects. The authors reported overall specificity of 78% and 72% sensitivity (Table 4) . 15 Two separate studies, from 2014 and 2013, reported the analysis of volatile organic compounds found in urine and breath, respectively.
The study examining urine used Field Asymmetric Ion Mobility Spectrometer (FAIMS): 133 patients were included; 83 colorectal cancer patients and 50 healthy controls. Sensitivity and specificity for colorectal cancer detection with FAIMS were 88% and 60% respectively. 16 A third technology, in the form of thermal-desorber gas chromatography-mass spectrometry, was used to assess volatile organic compounds in the study examining breath. Assessing the pattern of 15 compounds showed a sensitivity of 86%, a specificity of 83% and AUROC of 0.85. 17 More recently, using the same technique, this group described the ability of exhaled volatile organic compounds to discriminate between colorectal cancer patients before and after curative surgery. 18 33 Comparing the result of our study it would appear that volatile organic compounds have a greater diagnostic ability than either FOBt for the identification of colorectal cancer. In the future patient acceptability may be improved by the use of ingestible capsules. 34, 35 Further work is necessary to ascertain the source of the volatile organic compounds that were found in association with colorectal cancer and adenomas. It is likely that they are bacterial metabolites.
The driver-passenger model of colorectal cancer development suggests that Fusobacterium nucleatum is the key to ongoing tumourogenesis, with butanoic acid playing a key role in supporting the tumour microenvironment. 36 The presence of F. nucleatum in colorectal cancer tissue has also been noted in more advanced colorectal cancer, particularly those with lymph node metastasis, again supporting the positive correlation. 
| CONCLUSIONS
This pilot study has found compounds that are positively and negatively associated with the presence of colorectal neoplasia. Volatile organic compounds emitted from faeces can be utilised as a biomarker for colorectal cancer. Prospective studies are required to determine whether volatile organic compounds are better than FIT testing or whether they should be used together.
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